SARS-CoV-2

SARS-CoV-2
Name	SARS-CoV-2
Familia	Coronaviridae
Genus	Betacoronavirus

SARS-CoV-2 is a novel betacoronavirus first identified in late 2019 that caused the global COVID-19 pandemic, producing widespread morbidity and mortality and prompting unprecedented public health interventions by states, agencies, and institutions. The virus led to international coordination among organizations such as the World Health Organization, Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, National Institutes of Health and elicited research collaboration across universities like Harvard University, University of Oxford, Peking University, Johns Hopkins University and institutes including the Pasteur Institute, Gamaleya Research Institute, Ragon Institute. Major political actors including Xi Jinping, Donald Trump, Boris Johnson, Angela Merkel, Emmanuel Macron engaged in pandemic response, while events such as the 2020 United States presidential election, 2020 Summer Olympics and the G7 summit were affected.

Taxonomy and virology

SARS-CoV-2 belongs to the family Coronaviridae and the genus Betacoronavirus, related to viruses studied at institutions like the Wuhan Institute of Virology, Institut Pasteur, Rockefeller University, University of Cambridge and characterized using methods developed by researchers connected to awards such as the Nobel Prize. Virus classification referenced taxonomic decisions by bodies like the International Committee on Taxonomy of Viruses and described in reports from the World Health Organization, European Centre for Disease Prevention and Control and national agencies including the Public Health England and Robert Koch Institute. Laboratory investigations were conducted in biosafety facilities at centers including the Centers for Disease Control and Prevention and military medical institutions such as the Walter Reed Army Institute of Research.

Origin and early spread

Reports linking initial clusters to markets in Wuhan prompted epidemiological investigation involving teams from the Chinese Center for Disease Control and Prevention, the World Health Organization, Johns Hopkins University and the Lancet editorial board; subsequent international travel from hubs like Beijing Capital International Airport, Heathrow Airport, Hartsfield–Jackson Atlanta International Airport facilitated spread to cities including New York City, Milan, Madrid, São Paulo, Mumbai and Cape Town. Responses by national leaders in Italy, Spain, United States, China, South Korea, Japan and organizations such as the European Commission influenced containment, while historical comparisons were drawn with events like the 1918 influenza pandemic and outbreaks at sites such as the Diamond Princess (ship). Investigations into zoonotic origins invoked research from laboratories at the Wuhan Institute of Virology, field studies by scientists from the Chinese Academy of Sciences and comparisons with coronaviruses in bats studied by teams associated with the University of Hong Kong and the University of Sydney.

Genomic structure and mutations

The SARS-CoV-2 genome is a positive-sense single-stranded RNA molecule whose features were mapped using sequencing platforms from companies such as Illumina, Oxford Nanopore Technologies and analyzed in consortia like GISAID, Nextstrain and groups at Wellcome Sanger Institute and Broad Institute. Key coding regions include genes analogous to those characterized in studies at the Max Planck Institute, EMBL-EBI and Cold Spring Harbor Laboratory. Notable spike protein mutations and convergent evolution were tracked alongside variant designations referenced by advisory panels from the World Health Organization, European Centre for Disease Prevention and Control and national bodies like the Food and Drug Administration and Medicines and Healthcare products Regulatory Agency; sequencing surveillance programs at institutions including Public Health England and the National Institute for Biological Standards and Control informed public health guidance.

Transmission and pathogenesis

Transmission modes were investigated by teams at University College London, Imperial College London, Karolinska Institute, Massachusetts General Hospital and led to guidance from World Health Organization, Centers for Disease Control and Prevention and regional authorities such as State Council of the People's Republic of China and National Health Commission (China). Studies compared airborne, droplet and contact routes in venues like hospitals run by Mayo Clinic and Cleveland Clinic, and modeled spread using frameworks developed at Imperial College London and Johns Hopkins University. Pathogenesis research implicated host receptors studied at institutions including University of California, San Francisco, University of Pennsylvania and Columbia University, and immunopathology findings informed clinical trials coordinated by bodies such as the National Institutes of Health and pharmaceutical companies like Pfizer, Moderna, AstraZeneca, Sinovac.

Clinical features and diagnosis

Clinical syndromes ranged from asymptomatic infection detected in screening programs at airports like John F. Kennedy International Airport and facilities such as Mayo Clinic to severe disease requiring care at tertiary centers including Mount Sinai Hospital and Guy's and St Thomas' NHS Foundation Trust. Diagnostic methods developed by laboratory groups at Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific and academic labs used RT-PCR, antigen assays and serological tests validated against panels from National Institute for Biological Standards and Control and regulatory agencies like the Food and Drug Administration. Clinical management protocols were adopted by hospital systems in New York City, London, Milan, and recommendations evolved through panels convened by World Health Organization, National Institutes of Health and specialty societies such as the Infectious Diseases Society of America.

Prevention, treatment, and vaccines

Preventive measures promoted by World Health Organization, Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control and national ministries of health included non-pharmaceutical interventions implemented in cities like Wuhan, Seoul, Sydney, Berlin and Tokyo. Therapeutic research involved trials coordinated by the RECOVERY trial team at University of Oxford, the SOLIDARITY trial by the World Health Organization, and pharmaceutical development at companies including Pfizer, Moderna, AstraZeneca, Johnson & Johnson, Novavax and Sinopharm. Vaccination campaigns deployed products authorized by agencies such as the European Medicines Agency, Food and Drug Administration, National Medical Products Administration and distribution efforts involved logistics partners like UPS, DHL and state systems in United States, United Kingdom, China, India.

Public health impact and response

The pandemic prompted policy actions by bodies including the United Nations, G20, World Health Organization, European Union and national governments led by figures such as Joe Biden, Narendra Modi, Jair Bolsonaro, Scott Morrison; economic relief measures referenced legislations like relief acts in the United States Congress and stimulus packages managed by central banks including the Federal Reserve and European Central Bank. Impacts on sectors were noted in industries represented by exchanges such as the New York Stock Exchange, London Stock Exchange, Shanghai Stock Exchange and cultural events like the 2020 Summer Olympics and Cannes Film Festival were postponed or altered. Global health initiatives and funding from organizations like the Bill & Melinda Gates Foundation, Global Fund, Gavi shaped vaccine access and surveillance programs at public health institutes including Centers for Disease Control and Prevention and Africa CDC.

Category:Viruses